share_log

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42

HC Wainwright & Co.維持Tarsus Pharmicals的買入,將目標股價下調至42美元
Benzinga ·  2023/08/11 06:26

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $50 to $42.

HC Wainwright&Co.分析師Oren Livnat維持塔爾秀克斯製藥公司(納斯達克代碼:TARS)的買入,並將目標價從50美元下調至42美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論